Related Experiment Videos
Transplants across human leukocyte antigen barriers
Massimo F Martelli1, Franco Aversa, Ester Bachar-Lustig
1Department of Hematology, University of Perugia, Perugia, Italy.
Seminars in Hematology
|January 19, 2002
Summary
Full haplotype-mismatched stem cell transplants offer a viable option for high-risk acute leukemia. Advances in T-cell depletion and understanding donor Natural Killer cell activity have improved outcomes, reducing transplant-related mortality.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Haplotype-mismatched stem cell transplantation has a 20-year clinical history.
- Early leukemia transplant outcomes were poor due to graft-versus-host disease or rejection.
- Breakthroughs include megadose T-cell depletion and recognizing donor Natural Killer cell roles.
Purpose of the Study:
- To review the evolution and current status of full haplotype-mismatched stem cell transplantation.
- To highlight improvements in outcomes for high-risk acute leukemia patients.
- To establish mismatched transplants as a viable option.
Main Methods:
- Review of clinical experience with T-cell-depleted megadose progenitor cell transplants.
- Analysis of outcomes in high-risk acute leukemia patients.
- Comparison with unrelated matched transplants.
Main Results:
- Megadose T-cell-depleted transplants with high-intensity conditioning improve outcomes.
- Donor Natural Killer cell alloreactivity aids engraftment and prevents relapse.
- Reduced transplant-related mortality and favorable event-free survival reported.
- Outcomes compare favorably to unrelated matched transplants.
Conclusions:
- T-cell-depleted megadose stem cell transplants from immediately available mismatched family members are a viable option.
- This approach benefits candidates with high-risk acute leukemias.
- Advances have significantly improved survival and reduced complications.